Alexion Pharmaceuticals, Inc. ALXN
182.50 0.00 (+0.00%)
Apr 24, 2025, 3:47 PM EDT
180.21 Day range 182.67
52-week range unavailable
News
globenewswire.com Monopar to Present at AASLD – The Liver Meeting® 2026: Phase 3 FoCus Baseline Data and ALXN1840 Molybdenum Safety Data WILMETTE, Ill., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments…
seekingalpha.com Monopar: Licensing Agreement And Rolling NDA Submission Serve As Catalysts For 'Strong Buy' Monopar Therapeutics (MNPR) remains a "Strong Buy," driven by exclusive license rights to ALXN1840 for Wilson disease and ongoing radiotherapeutic development. Completion of the rolling NDA for…
globenewswire.com Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease WILMETTE, Ill., July 22, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments…
seekingalpha.com Monopar Therapeutics: ALXN1840's Bull Case Has Improved Monopar Therapeutics has evolved from early radiopharma assets into a more concrete bet with ALXN1840 for rare diseases. ALXN1840 is their Wilson disease asset, which currently has a much clearer…
globenewswire.com Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease WILMETTE, Ill., June 30, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments…
globenewswire.com Monopar Presents Phase 2 ALXN1840 Data Demonstrating Liver Disease Stabilization and Neurologic Improvement in Treatment-Experienced Wilson Disease Patients at EASL 2026 WILMETTE, Ill., June 01, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments…
globenewswire.com Monopar Announces Publication of Phase 2 Study Demonstrating ALXN1840 Significantly Improves Copper Balance in Patients with Wilson Disease WILMETTE, Ill., May 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for…
globenewswire.com Monopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026 WILMETTE, Ill., April 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments…
benzinga.com Royalty Rift: Alexion Cuts Off US Royalty Payments To Xencor On Wednesday, Xencor Inc. (NASDAQ: XNCR) said it is revising its revenue outlook for royalties tied to Ultomiris.
globenewswire.com Monopar Announces Journal of Hepatology Publishes Physicians' Letter to the Editor Demonstrating ALXN1840 Rapidly Improved Copper Balance in Wilson Disease Patients WILMETTE, Ill., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar” or the “Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative treatments…
businesswire.com JCR Pharmaceuticals and Alexion Achieve Milestone in Collaborative Neurodegenerative Disease Program HYOGO, Japan--(BUSINESS WIRE)--JCR announced that is has achieved a key research milestone in one of its collaborative programs with Alexion, AstraZeneca Rare Disease.
seekingalpha.com Monopar Therapeutics: A Speculative Buy On 2 Fronts With Catalysts Imminent Monopar Therapeutics Inc. is a clinical-stage biotech with two promising programs: ALXN1840 for Wilson disease and a radiopharmaceuticals pipeline targeting advanced cancers. ALXN1840 has shown…
globenewswire.com Monopar Presents ALXN1840 Late-Breaker Data at EASL 2025 WILMETTE, Ill., May 07, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with…
globenewswire.com Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025 WILMETTE, Ill., April 29, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with…
businesswire.com JCR Pharmaceuticals Announces Achievement of Milestone Using J-Brain Cargo® Technology for Neurodegenerative Disease in Research Collaboration with Alexion HYOGO, Japan--(BUSINESS WIRE)--JCR Pharmaceuticals announces achievement of milestone using J-Brain Cargo® for neurodegenerative disease in research collaboration with Alexion.
seekingalpha.com 5 Biotech Acquisition Targets To Accumulate In 2024 Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they…
businesswire.com JCR Announces Research Collaboration, Option and License Agreement with Alexion on Discovery of Oligonucleotide Therapeutics Using J-Brain Cargo® Technology HYOGO, Japan--(BUSINESS WIRE)--JCR announced an agreement with Alexion for the development of novel oligonucleotide therapeutics to support targeted delivery using J-Brain Cargo®.
proactiveinvestors.com AstraZeneca and Alexion working with FDA on US label expansion for Ultomiris AstraZeneca PLC (LSE:AZN) said the US Food and Drug Administration (FDA) has responded to a request to expand the use of the drug Ultomiris by asking for a risk evaluation and mitigation strategy. In…
prnewswire.com BioLight announces a joint cooperation agreement with Alexion (AstraZeneca Rare Disease) to explore an innovative technology based on natural tears for the diagnosis of retinal diseases TEL AVIV, Israel , May 30, 2023 /PRNewswire/ -- BioLight (TASE: BOLT) is proud to report it has signed a research collaboration agreement with Alexion (AstraZeneca Rare Disease), focusing on…
businesswire.com JCR Pharmaceuticals Announces Research Collaboration, Option and License Agreement with Alexion to Develop a Therapy Using J-Brain CargoⓇ for Neurodegenerative Disease HYOGO, Japan--(BUSINESS WIRE)--JCR announced that the company signed a Research Collaboration, Option and License Agreement with Alexion to Develop a Therapy Using J-Brain Cargo.
benzinga.com Stocks That Hit 52-Week Highs On Wednesday Before 10 a.m. ET Wednesday, 81 stocks made new 52-week highs.
benzinga.com Stocks That Hit 52-Week Highs On Monday During the morning session on Monday, 118 stocks hit new 52-week highs.
benzinga.com Stocks That Hit 52-Week Highs On Wednesday Before 10 a.m. ET on Wednesday, 105 companies hit new 52-week highs.
benzinga.com Stocks That Hit 52-Week Highs On Friday During Friday's morning session, 235 stocks hit new 52-week highs.- benzinga.com Stocks That Hit 52-Week Highs On Thursday Before 10 a.m. ET on Thursday, 258 companies set new 52-week highs.
benzinga.com 5 Top ETFs With Exposure To Biogen For the first time in 18 years, there was a new treatment for Alzheimer’s Disease approved by the FDA.- benzinga.com Stocks That Hit 52-Week Highs On Thursday Before 10 a.m. ET Thursday, 56 stocks made new 52-week highs.
benzinga.com Stocks That Hit 52-Week Highs On Tuesday Tuesday's morning session saw 241 companies set new 52-week highs.- benzinga.com Stocks That Hit 52-Week Highs On Monday Before 10 a.m. ET on Monday, 131 companies set new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Friday During Friday's morning session, 127 stocks hit new 52-week highs.
benzinga.com Stocks That Hit 52-Week Highs On Wednesday During Wednesday's morning trading, 57 companies set new 52-week highs.- benzinga.com Stocks That Hit 52-Week Highs On Friday Friday's morning session saw 136 companies set new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Wednesday Before 10 a.m. ET on Wednesday, 140 companies hit new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Tuesday This morning 147 companies reached new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Monday Before 10 a.m. ET Monday, 197 stocks hit new 52-week highs.
benzinga.com Stocks That Hit 52-Week Highs On Friday Friday's morning session saw 420 companies set new 52-week highs.
benzinga.com Stocks That Hit 52-Week Highs On Tuesday This morning 163 companies set new 52-week highs.- benzinga.com Stocks That Hit 52-Week Highs On Monday During the morning session on Monday, 372 stocks hit new 52-week highs.
benzinga.com Stocks That Hit 52-Week Highs On Monday Monday's morning session saw 240 companies set new 52-week highs.- benzinga.com 3 ETFs For AstraZeneca's $39B Alexion Pharmaceuticals Takeover The biotechnology space is always fertile territory for mergers and acquisitions, and that theme was on display over the weekend when AstraZeneca (NYSE: AZN) announced a
- benzinga.com Earnings Scheduled For October 29, 2020 Companies Reporting Before The Bell • PG&E (NYSE:PCG) is likely to report quarterly earnings at $0.27 per share on revenue of $4.72 billion.
- benzinga.com Stocks That Hit 52-Week Highs On Thursday During the morning session on Thursday, 186 stocks hit new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Lows On Monday
- benzinga.com Stocks That Hit 52-Week Lows On Thursday
- benzinga.com Stocks That Hit 52-Week Lows On Friday
- benzinga.com Stocks That Hit 52-Week Lows On Friday
- benzinga.com Stocks That Hit 52-Week Lows On Thursday
- benzinga.com Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018
- benzinga.com Earnings Scheduled For October 24, 2018
- benzinga.com 51 Biggest Movers From Yesterday